|Ms. Valerie Barber Palmieri||CEO, Pres & Director||544.43k||N/A||1961|
|Mr. Robert Harry Beechey CPA||Chief Financial Officer||364.68k||N/A||1963|
|Ms. Kaile Zagger||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Lesley Northrop Ph.D.||Chief Science Officer||N/A||N/A||N/A|
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. Aspira Women's Health Inc. has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test. It serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.
Aspira Women's Health Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.